New findings may improve the treatment of prostate cancer

This forum will be a place for listing other useful molecular biology-related web portals and/or site announcements.

Moderator: Suzanne

New findings may improve the treatment of prostate cancer

Postby whbio » Apr 17 2017 1:20 pm

New study provides a new marker for the diagnosis and treatment of prostate cancer, the most frequently diagnosed malignancy in adult men in developed countries.

In the US, one out of five men will be diagnosed with prostate cancer. Even though mortality has fallen significantly over the past twenty years, there are still several challenges to reducing morbidity and mortality of the cancer.

Early detection is very important for the success of treatment. Prostate-specific antigen (PSA) is the most commonly used blood marker for prostate cancer. The blood level of PSA is often increased in men with prostate cancer. However, many benign conditions such as inflammation can also cause a man’s PSA level to increase. More reliable markers for prostate cancer are in need.

The new study has shown that a protein called TSPYL5 may help identify prostate cancer progression and therefore lead to personalized therapies for patients.The study is carried out by Senthil Kumar, Jeffrey Bryan, Magda Esebua, James Amos-Landgraf and Tanner May from the University of Missouri.

In the work, first author Kumar and colleagues examined prostate cancer samples at various stages of the disease. Immunohistochemical studies clearly identified TSPYL5 in benign tissue and in tumors with Gleason score of 6 and 7. By contrast, the levels of the protein were very low in tumors with Gleason score of 8 and above. The researchers also found that the presence of TSPYL5 appeared to increase prostate cancer cells’ sensitivity to chemotherapy drugs.

Taken together, the findings suggest that measuring the levels of TSPYL5 might be a way to determine which patients have more aggressive disease and which patients are more likely to respond to treatment.

The study, titled "Testis specific Y-like 5: gene expression, methylation and implications for drug sensitivity in prostate carcinoma," appears in BMC Cancer. Get to know more at http://www.cusabio.com/
whbio
supertech
supertech
 
Posts: 68
Joined: Nov 02 2016 10:19 am

Return to Other Web Portals and Sites

Who is online

Users browsing this forum: No registered users and 1 guest